UK Health Bill: Three Amendments Tabled in September 2026 to Enable Legislative Powers for a Future Medical Device Licensing Regime

Published: 14 October 2026, 09:32

Category: Registration and Market Access

What Happened

On 1 September 2026, the UK government tabled three amendments to the Health Bill in Parliament. The amendments address the legislative framework for the regulation of medicines and medical devices. They form part of a broader package of reforms, and the Medicines and Healthcare products Regulatory Agency (MHRA) is within the scope of those reforms. According to the government, the amendments remain subject to parliamentary scrutiny.

The proposals do not immediately change current regulatory requirements. Any provisions that are passed would require further development and public consultation before implementation.

What the Three Amendments Cover

First Amendment: Information-Sharing Powers

The MHRA would be given a clearer legal basis to share specified information about medicines and medical devices with relevant UK government bodies and overseas regulatory partners, where this supports public health and patient safety, as well as innovation, access and effective regulation. Existing safeguards would remain unchanged; sharing would still be subject to statutory conditions and necessity requirements. Commercially sensitive information and patient information would continue to be protected by data protection legislation, patient consent and related measures.

Second Amendment: Easier Updating of Regulation

The proposal would allow legislation to follow subsequent updates to technical standards and international guidelines automatically, so that changes can take effect as they are made. Consultation arrangements would also be adjusted: minor changes would use targeted engagement, while major policy reforms would retain full public consultation. Some technical or administrative minor adjustments could be incorporated directly into legislation if Parliament does not object.

Third Amendment: Powers for a Future Medical Device Licensing Regime

The third amendment would amend the Medicines and Medical Devices Act 2021 to create the legal foundation for a future licensing framework. This amendment would only create enabling powers; the detailed regime would still require further policy work, public consultation, impact assessment and, ultimately, parliamentary scrutiny.

What the Licensing Regime Could Look Like

The government describes a direction that is being explored. In the future, devices entering the Great Britain market through a UK route could require a licence issued by the MHRA, rather than relying only on certification by third-party conformity assessment bodies. The system would be risk-based, with different levels of review depending on the nature of the product.

The government gives two reasons. First, to improve the capacity and resilience of medical device regulation in Great Britain. Second, to make the framework better suited to fast-changing technologies such as software and artificial-intelligence-enabled medical devices.

One point should be noted: until legislation comes into force, these are not obligations that companies must comply with today.

What About the Current Status?

The government's explanatory notes are clear. Until a future model takes shape, the UKCA system continues to apply in Great Britain. The policy intent concerning international mutual recognition and recognition has not changed.

Northern Ireland is treated separately. Under the Windsor Framework, it continues to apply the EU Medical Devices Regulation (EU MDR) and In Vitro Diagnostic Regulation (EU IVDR), in order to maintain dual access to the EU single market and the UK internal market.

Sources and Scope

Source: UK Government (GOV.UK) news release, 'MHRA regulatory reform amendments tabled in Government's Health Bill', published 1 September 2026.

https://www.gov.uk/government/news/mhra-regulatory-reform-amendments-tabled-in-governments-health-bill

Verification scope and access date: The full GOV.UK news release above was reviewed, together with publicly available information on MHRA medical device regulatory reform; access date: 14 October 2026.

Scope note: This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. The amendments remain under parliamentary scrutiny. The final text and timetable should be based on the official legal texts formally issued by the UK government and the MHRA, and information may change with subsequent official updates.

Information sources:

• UK Government (GOV.UK) — MHRA regulatory reform amendments tabled in Government's Health Bill, 2026-09-01.
• UK Government (GOV.UK) — Medical devices: EU regulations for MDR and IVDR (Windsor Framework).

AIMEILI Regulatory Interpretation

These amendments are enabling measures, not a new compliance regime. The key regulatory signal is that the UK is preserving the option to create an MHRA-issued licence for medical devices placed on the Great Britain market via a UK route. If implemented, this could shift part of the market-access control from third-party conformity assessment to a regulator-issued authorisation. The risk-based design suggests that review intensity would vary by device class and technology type. The information-sharing and standards-updating amendments are supporting changes: they would give the MHRA clearer legal grounds for sharing regulatory information with domestic and international partners, and make it easier for UK rules to track evolving technical standards and international guidance.

For now, the existing UKCA framework remains in force in Great Britain. Northern Ireland continues to follow EU MDR and EU IVDR under the Windsor Framework. Companies should not treat the amendments as immediate requirements. However, they should monitor the parliamentary process, any public consultation, and the MHRA's policy development, because these will determine whether a licensing route is introduced, how it interacts with UKCA, and what transition arrangements may apply.

Business Impact

Manufacturers, distributors, CROs and regulatory affairs teams should assess the potential medium- to long-term impact on UK market-access strategy. If a future MHRA licensing system is introduced, companies may need to prepare for an additional or alternative authorisation pathway for Great Britain, with risk-based review requirements, potential fees, timelines, and technical documentation expectations. Portfolio segmentation by device risk, software content and reliance on third-party certification would help identify products most likely to be affected.

Regulatory intelligence and horizon-scanning should track the Health Bill's progress, consultation announcements and MHRA guidance. Companies with UKCA certificates or UK Responsible Person arrangements should maintain current compliance while avoiding premature changes based only on enabling powers. For Northern Ireland, EU MDR and EU IVDR compliance remains central. Distributors and CROs may see demand for gap assessments, regulatory strategy, clinical evidence planning and post-market surveillance support if a UK licensing regime advances.

Overall, the amendments create legislative optionality. They do not yet change day-to-day registration obligations. The practical task now is to monitor, map exposure and prepare scenario plans rather than to submit new applications or redesign UKCA compliance on the basis of the proposals alone.